This is the authors' abstract. We don't add key points for this paper.
Great hope is placed in the use of RNA interference in the development of novel therapeutics. Recently, small interfering RNAs (siRNAs) were delivered to tumor cells of melanoma patients by nanoparticles consisting of a cyclodextrin polymer, and polyethylene glycol coupled to adamantane and transferrin (see picture). It was demonstrated that the target mRNA in the patients was degraded by a specific RNA interference mechanism.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jens Kurreck (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: